InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,549.38
(
0.73%
)
US TECH 100
19,744.00
(
0.52%
)
Dow Jones
39,312.64
(
0.01%
)
Brent Oil
87.58
(
0.28%
)
Bitcoin
56,353.57
(
-1.10%
)
Post# of 158400
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

d5wr59mfi8

Send PM Follow Ignore
Followers 63
Posts 3143
Boards Moderated 0
Alias Born 03/06/2014

d5wr59mfi8

Re: cwwan1 post# 121189

Sunday, 03/23/2014 1:08:40 PM

Sunday, March 23, 2014 1:08:40 PM

Post# of 158400
The business model allows for the reduction of both cost and time. Selling or licencing treatments after Phase II greatly reduces costs and saves time. Not having to further the development in relation to marketing after Phase III also saves time and money.
Outsourcing most of the pre-clinical and clinical trails reduces overhead, this may not be specific to Regen, but still a good practice for business.

Not to mention the way patents are found, licensed, and eventually re-patented. This saves a ton of time as some treatments are not made from scratch.

The opinions, comments, or concerns, expressed herein, are solely that of the screen name 'd5wr59mfi8'. They are not to be misconstrued as legal or financial advice and should not be followed. For financial advice, please see the guidance of financial p

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up